All In Biotech

Drug Trial Radar · NCT06581406

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Dec 17, 2024

Primary completion

Jan 2030

Study completion Oct 2031

Sponsor

Lead sponsor
Replimune, Inc.Industry
Sponsor type
Industry
First posted
Sep 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

Conditions

  • Metastatic Uveal Melanoma

Interventions

  • RP2Biological

    Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.

  • IpilimumabBiological

    Ipilimumab: human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody

  • NivolumabBiological

    Nivolumab: Anti-PD-1 Monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From Day 1 up to 3 years after last dose.
  2. Progression Free Survival (PFS)Time frame: From Day 1 up to 3 years after last dose.

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Insisute

    Scottsdale, Arizona · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • The Angeles Clinic and Research Institute

    Los Angeles, California · Recruiting

  • University of California Los Angeles

    Los Angeles, California · Recruiting

  • Stanford Cancer Institute

    Palo Alto, California · Recruiting

  • University of Colorado Hospital - Anschutz Cancer Pavilion(ACP)

    Aurora, Colorado · Recruiting

  • The Melanoma & Skin Cancer Institute

    Englewood, Colorado · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic - Jacksonville FL

    Jacksonville, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • The West Clinic, PLLC dba West Cancer Center

    Germantown, Tennessee · Recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic)

    Nashville, Tennessee · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • The University Of Texas Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • University Of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin · Recruiting

  • Melanoma Institute Australia

    Wollstonecraft, New South Wales, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • The Royal Marsden NHS Foundation Trust

    London, United Kingdom · Recruiting

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Liverpool, Merseyside, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.